Literature DB >> 18063729

Review: rosiglitazone increases risk of MI but does not differ from other drugs for CV death in type 2 diabetes.

Mark A Hlatky1, Dena M Bravata.   

Abstract

Entities:  

Year:  2007        PMID: 18063729     DOI: 10.1136/ebm.12.6.169

Source DB:  PubMed          Journal:  Evid Based Med        ISSN: 1356-5524


× No keyword cloud information.
  2 in total

1.  Setting the record straight on TIDE: a lost opportunity for patients with diabetes.

Authors:  Zubin Punthakee; Jackie Bosch; Hertzel C Gerstein
Journal:  Diabetologia       Date:  2013-06-06       Impact factor: 10.122

2.  Meta-analysis in medical research.

Authors:  A B Haidich
Journal:  Hippokratia       Date:  2010-12       Impact factor: 0.471

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.